Discovery of Cellular Mechanism of Action of tACPA in Rheumatoid Arthritis
News Jun 11, 2015
ModiQuest B.V. has announced that it has discovered the cellular mechanism of action of its therapeutic anti-citrullinated protein lead antibodies (tACPA) for the treatment of rheumatoid arthritis (RA) and other diseases.
To accelerate tACPA development towards clinical Proof of Concept, facilitate funding, and attract a development partner, Citryll B.V. was founded as a single asset drug development company.
The tACPAs are active in different validated RA animal models and models for other human diseases. They exert their therapeutic effect by inhibiting the formation of Neutrophil extracellular traps (NETs) as shown with primary human neutrophils. NETs are extracellular lattices of decondensed chromatin decorated with antimicrobial factors, whose function is to eliminate invading microorganisms.
Dysregulated NETosis constitutes a pathogenic mechanism in autoimmune and sterile inflammatory diseases. This offers novel therapeutic opportunities for diseases with unmet medical needs, including RA, where existing treatments can have serious side-effects and comprise a significant percentage of non-responders. NETosis is peptidyl arginine deiminase (PAD) dependent, creating neo-epitopes that trigger autoimmunity and breaking of tolerance in RA.
ModiQuest has discovered tACPAs using its proprietary antibody generation technology platforms ModiFuse™ (highly efficient hybridoma electrofusion technology), ModiSelect™ (B cell selection technology for low immunogenic or multiple antigen targets) and ModiPhage™ (proprietary phage display libraries).
All three technology platforms are also used by ModiQuest’s service business, ModiQuest Research B.V., for custom antibody lead generation in third party service projects with a recent addition of an innovative platform for difficult antibody drug targets, ModiVacc™.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
'Universal Antibodies' Disarm Various PathogensNews
Based on the sugar structures on their surface, bacteria can be classified in subgroups. As a rule, an antibody eliminates only one subgroup and does not protect against other microbes. However, in studies with the bacterium Klebsiella pneumoniae, researchers have now been the first to find that the immune system also produces antibodies that recognize and neutralize various microorganisms.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018